Drug intelligence / Profile preview

timtraxanib

Development stage: Unknown
Lead developer: Avixgen
Modality: Peptides, Small Molecules
Administration: Ophthalmic

Overview

Timtraxanib (AVI-3207) is a peptide-based small molecule drug developed primarily for the treatment of age-related macular degeneration and retinal degeneration. It acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR2), thereby inhibiting angiogenesis by blocking VEGFR2-mediated signaling pathways that promote endothelial cell proliferation and migration. This targeted inhibition reduces abnormal blood vessel formation in the retina, which is central to diseases like age-related macular degeneration. Timtraxanib is being developed by Avixgen and has reached Phase I clinical trials for age-related macular degeneration[1][3][4][8].

Other names: timtraxanibAVI-3207AVI3207AVI 3207

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)

Beyond the preview

Go deeper on timtraxanib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on timtraxanib.

Explore the full profile